Conference Track

Clinical Updates in HCV Treatment

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Combination Therapy of Peginterferon alfa-2a and Valopicitabine 200 mg Once Daily Tolerable and End of Treatment Response in Half of Treatment-Naive HCV Genotype 1 Patients
PROVE 1 Study Shows Higher Rates of Undetectable Virus at Week 4 and 12 of Therapy With Telaprevir vs Placebo When Combined With Peginterferon and Ribavirin in Treatment-Naive HCV Genotype 1 Patients
Addition of Ribavirin to Recombinant Interferon Omega Improves Viral Response in Treatment-Naive Chronically HCV Genotype 1–Infected Patients
Albumin Interferon Alfa-2b/Ribavirin Produces Potent Virologic Response in Patients With Chronic HCV Genotype 2/3 Infection
VISER2: Taribavirin Associated With Significantly Lower SVR Rates than Ribavirin, Except at Higher Doses
Week 4 Plasma Ribavirin Concentration Independent Predictor of SVR in HCV-Infected Patients—Optimal Cutoff Suggested
Extending Peginterferon alfa Plus Weight-Based Ribavirin May Improve SVR Rate in HCV Genotype 1 Slow Responder Patients
Short-term Treatment With Higher-Dose BILB 1941 Demonstrates Favorable Antiviral Activity but Poor GI Tolerability in HCV Genotype 1 Patients
HCV Genotype 1/4 Patients With Poor Renal Function May Benefit From Ribavirin Dosing Based on GFR, Not Weight
Greater Anti-HCV Activity With HCV-796 Plus Peginterferon alfa-2b Than With Peginterferon alfa-2b Alone
Numerical Trend Toward Greater HCV RNA Decline With Taribavirin Predosing Prior to Initiation of Peginterferon alfa-2b Plus Taribavirin
Proof of Concept Study: NS4A Antagonist ACH-806 Effective in HCV-Infected Patients but Side Effects Limits Further Development
Week 12 Posttreatment Response Rates With Albinterferon-Based Therapy in Hepatitis C Patients Comparable to Standard of Care

Expert Analysis

Clinical Updates in HCV Treatment

Faculty:

Peter Ferenci, MD
Ira M. Jacobson, MD
Karen L. Lindsay, MD, MMM

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe data regarding the safety and efficacy of novel therapies for HCV in treatment-naive and treatment-experienced patients
Specify the latest data available on efficacy and durability of currently available HCV therapies
Review recent studies of methods for monitoring and individualizing HCV therapy

CREDIT INFORMATION

Release Date: June 27, 2007

Expiration Date: June 26, 2008

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing contact hours

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.